Viridian Therapeutics (NASDAQ:VRDN) Trading 4.9% Higher

Viridian Therapeutics, Inc. (NASDAQ:VRDN)’s stock price shot up 4.9% during mid-day trading on Monday . The stock traded as high as $13.20 and last traded at $13.19. 97,024 shares were traded during trading, a decline of 90% from the average session volume of 958,474 shares. The stock had previously closed at $12.57.

Analyst Ratings Changes

A number of equities analysts have recently commented on VRDN shares. Oppenheimer cut their price target on Viridian Therapeutics from $36.00 to $31.00 and set an “outperform” rating for the company in a report on Thursday, May 9th. LADENBURG THALM/SH SH lowered Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. Wedbush increased their price target on shares of Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. The Goldman Sachs Group assumed coverage on shares of Viridian Therapeutics in a research report on Thursday, June 6th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Viridian Therapeutics Trading Down 3.4 %

The company has a quick ratio of 23.99, a current ratio of 23.99 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $814.34 million, a P/E ratio of -2.84 and a beta of 1.03. The firm’s 50-day simple moving average is $13.25 and its 200-day simple moving average is $17.13.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.28. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 75,737.85% and a negative return on equity of 92.04%. The firm’s revenue was down 26.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.61) EPS. Analysts anticipate that Viridian Therapeutics, Inc. will post -3.61 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its position in Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after buying an additional 799 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Viridian Therapeutics by 122.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock worth $182,000 after acquiring an additional 4,610 shares during the last quarter. Arizona State Retirement System bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at $208,000. Principal Financial Group Inc. raised its position in Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after purchasing an additional 1,058 shares during the period. Finally, Dark Forest Capital Management LP bought a new stake in Viridian Therapeutics in the third quarter worth $264,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.